/
Navigation
Chronicles
Browse all articles
Explore
Semantic exploration
Research
Entity momentum
Nexus
Correlations & relationships
Story Arc
Topic evolution
Drift Map
Semantic trajectory animation
Posts
Analysis & commentary
Pulse API
Tech news intelligence API
Browse
Entities
Companies, people, products, technologies
Domains
Browse by publication source
Handles
Browse by social media handle
Detection
Concept Search
Semantic similarity search
High Impact Stories
Top coverage by position
Sentiment Analysis
Positive/negative coverage
Anomaly Detection
Unusual coverage patterns
Analysis
Rivalry Report
Compare two entities head-to-head
Semantic Pivots
Narrative discontinuities
Crisis Response
Event recovery patterns
Connected
Search: /
Command: ⌘K
Embeddings: large
TEXXR

Chronicles

The story behind the story

days · browse · Enter similar · o open

Singapore- and NYC-based Holmusk, which offers real-world clinical data and analytics for the behavioral health industry, raised a $45M Series B led by Veradigm

Rachel Chitra / DealStreetAsia :

DealStreetAsia Rachel Chitra

Context & Ripple Effects

Behavioral health has been drawing venture money across every layer of the stack: Intellect raised $10M to extend its employer-side mental health benefits, Grow Therapy pulled in a $75M Series B for provider practice tools, and the space's earlier wave included Quartet Health's $40M Series B back in 2016. What nearly all of that funding built was care delivery or access.

Holmusk sits on a different layer: real-world clinical data and analytics for behavioral health, and the fact that Veradigm — a health IT operator, not a typical growth fund — led the $45M Series B signals that incumbents want proprietary evidence assets attached to their platforms.

First-order effects

  • Holmusk gets the capital to scale its behavioral health data assets, while Veradigm secures a preferred relationship with the evidence layer its own products increasingly need.
  • Care-delivery rivals like Grow Therapy and Quartet Health now compete against a funded player whose product is proof of outcomes rather than another channel of care.

Second-order effects

  • Payers and employers buying from delivery-side vendors can start demanding measured results, forcing providers of virtual practices and benefit programs to buy or partner for analytics they don't have in-house.
  • Veradigm's lead position pressures other health IT platforms to either acquire or invest in real-world data capabilities rather than license them at arm's length.

Third-order effects

  • If the pattern holds, behavioral health splits into a delivery tier and an evidence tier, with reimbursement and enterprise contracts increasingly gated on real-world outcome data that only a few funded specialists control.
  • A strategic-led round like this points toward consolidation where data infrastructure becomes the acquisition target for health IT roll-ups, not just another SaaS category.

The trend: Venture and strategic capital in behavioral health is shifting from funding new channels of care to funding the data and evidence infrastructure that decides which care gets paid for.